Top

Published in:

01-12-2009 | Original Article

Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers

Authors: Jung Ho Kim, So Hyun Shin, Hyeong Ju Kwon, Nam Yun Cho, Gyeong Hoon Kang

Published in: Virchows Archiv | Issue 6/2009

Abstract

CpG island methylator phenotype (CIMP) refers to a subset of colorectal cancers (CRCs) that are characterized by concordant hypermethylation of multiple CpG island loci. CIMP+ CRCs have peculiar clinicopathological features. However, controversy exists over prognostic implications of CIMP in CRCs. We analyzed 320 cases of CRCs for their CIMP status using the MethyLight assay and determined clinicopathological features and prognostic implications of CIMP alone or in combination with microsatellite instability (MSI). With methylation of five or more markers among eight markers examined, CIMP+ tumors were significantly associated with female gender, proximal tumor location, poor differentiation, nodal metastasis, more advanced cancer, BRAF mutations, MSI, and poor prognosis (all P values <0.05). Ogino’s combined eight-marker panel outperformed the Ogino and the Laird five-marker panels in detecting these features. Of the four molecular subtypes generated by the combination of CIMP and MSI status, the CIMP+/MSI− subtype showed the worst clinical outcome (P = 0.0003). However, poor prognosis of CIMP+/MSI− subtype was found to be attributed to BRAF mutation. In conclusion, the CIMP+/MSI− subtype tends to present with distinct clinicopathological and molecular features and shows the worst clinical outcome among the four molecular subtypes of CRCs.

Available only for authorised users

Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72:141–196CrossRefPubMed

Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225–3229PubMed

Bird AP, Wolffe AP (1999) Methylation-induced repression—belts, braces, and chromatin. Cell 99:451–454CrossRefPubMed

Wood LD, Parsons DW, Jones S et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 318:1108–1113CrossRefPubMed

Schuebel KE, Chen W, Cope L et al (2007) Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 3:1709–1723CrossRefPubMed

Toyota M, Ahuja N, Ohe-Toyota M et al (1999) CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96:8681–8686CrossRefPubMed

Weisenberger DJ, Siegmund KD, Campan M et al (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38:787–793CrossRefPubMed

Ogino S, Cantor M, Kawasaki T et al (2006) CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 55:1000–1006CrossRefPubMed

Nagasaka T, Koi M, Kloor M et al (2008) Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology 134:1950–1960.e1CrossRefPubMed

10.

Shen L, Toyota M, Kondo Y et al (2007) Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 104:18654–18659CrossRefPubMed

11.

Lee S, Cho NY, Yoo EJ, Kim JH, Kang GH (2008) CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch Pathol Lab Med 132:1657–1665PubMed

12.

Ward RL, Cheong K, Ku SL et al (2003) Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol 21:3729–3736CrossRefPubMed

13.

Shen L, Catalano PJ, Benson AB 3rd et al (2007) Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 13:6093–6098CrossRefPubMed

14.

Barault L, Charon-Barra C, Jooste V et al (2008) Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 68:8541–8546CrossRefPubMed

15.

Samowitz WS, Sweeney C, Herrick J et al (2005) Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65:6063–6069CrossRefPubMed

16.

Ogino S, Goel A (2008) Molecular classification and correlates in colorectal cancer. J Mol Diagnostics 10:13–27CrossRef

17.

Yoo EJ, Park SY, Cho NY et al (2008) Helicobacter pylori-infection-associated CpG island hypermethylation in the stomach and its possible association with polycomb repressive marks. Virchows Arch 452:515–524CrossRefPubMed

18.

Kang GH, Lee S, Cho NY et al (2008) DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest 88:161–170CrossRefPubMed

19.

Weisenberger DJ, Campan M, Long TI et al (2005) Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 33:6823–6836CrossRefPubMed

20.

Lee S, Cho NY, Choi M et al (2008) Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int 58:104–113CrossRefPubMed

21.

Ogino S, Kawasaki T, Kirkner GJ et al (2007) Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagnostics 9:305–314CrossRef

22.

Georgiades IB, Curtis LJ, Morris RM, Bird CC, Wyllie AH (1999) Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability. Oncogene 18:7933–7940CrossRefPubMed

23.

Goel A, Arnold CN, Niedzwiecki D et al (2003) Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res 63:1608–1614PubMed

24.

Cheng YW, Pincas H, Bacolod MD et al (2008) CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. Clin Cancer Res 14:6005–6013CrossRefPubMed

25.

Goel A, Nagasaka T, Arnold CN et al (2007) The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 132:127–138CrossRefPubMed

26.

Ogino S, Nosho K, Kirkner GJ et al (2009) CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58:90–96CrossRefPubMed

27.

Herman JG, Umar A, Polyak K et al (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95:6870–6875CrossRefPubMed

28.

Kuismanen SA, Holmberg MT, Salovaara R, de la Chapelle A, Peltomaki P (2000) Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol 156:1773–1779PubMed

29.

Cunningham JM, Christensen ER, Tester DJ et al (1998) Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58:3455–3460PubMed

30.

Cunningham JM, Kim CY, Christensen ER et al (2001) The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 69:780–790CrossRefPubMed

31.

Yuen ST, Davies H, Chan TL et al (2002) Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62:6451–6455PubMed

32.

Chang SC, Lin JK, Yang SH et al (2006) Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer 118:1721–1727CrossRefPubMed

33.

Nagasaka T, Sasamoto H, Notohara K et al (2004) Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 22:4584–4594CrossRefPubMed

34.

Fransen K, Klintenas M, Osterstrom A et al (2004) Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25:527–533CrossRefPubMed

35.

Vilkin A, Niv Y, Nagasaka T et al (2009) Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel. Cancer 115:760–769CrossRefPubMed

36.

Young J, Barker MA, Simms LA et al (2005) Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. Clin Gastroenterol Hepatol 3:254–263CrossRefPubMed

37.

Samowitz WS, Slattery ML, Sweeney C et al (2007) APC mutations and other genetic and epigenetic changes in colon cancer. Mol Cancer Res 5:165–170CrossRefPubMed

38.

Tanaka H, Deng G, Matsuzaki K et al (2006) BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. Int J Cancer 118:2765–2771CrossRefPubMed

39.

Rajagopalan H, Bardelli A, Lengauer C et al (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418:934CrossRefPubMed

40.

Oliveira C, Pinto M, Duval A et al (2003) BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 22:9192–9196CrossRefPubMed

41.

Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS (2006) CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagnostics 8:582–588CrossRef

42.

Rashid A, Shen L, Morris JS, Issa JP, Hamilton SR (2001) CpG island methylation in colorectal adenomas. Am J Pathol 159:1129–1135PubMed

43.

Jass JR, Baker K, Zlobec I et al (2006) Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a ‘fusion’ pathway to colorectal cancer. Histopathology 49:121–131CrossRefPubMed

44.

Kakar S, Deng G, Cun L, Sahai V, Kim YS (2008) CpG island methylation is frequently present in tubulovillous and villous adenomas and correlates with size, site, and villous component. Hum Pathol 39:30–36CrossRefPubMed

Title: Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers
Authors: Jung Ho Kim
So Hyun Shin
Hyeong Ju Kwon
Nam Yun Cho
Gyeong Hoon Kang
Publication date: 01-12-2009
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 6/2009
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-009-0857-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2009

Encapsulated apocrine papillary carcinoma of the breast—a tumour of uncertain malignant potential: report of five cases

Colonic carcinoma with a pancreatic acinar cell differentiation. A case report

Borderline and malignant phyllodes tumors display similar promoter methylation profiles

Immunosuppressive cytokine Interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort

Expression of MMP-10, MMP-21, MMP-26, and MMP-28 in Merkel cell carcinoma

Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2